Molecular Biology Program
The Dirk Remus Lab
We are interested in the mechanism of chromosome replication, a process that is highly conserved across eukaryotes and that involves the duplication of both the chromosomal DNA and its associated chromatin states. As chromosomes are the carriers of both the genetic and epigenetic information, faithful chromosome replication is of fundamental importance for genome maintenance during normal cell proliferation. Accordingly, defects in chromosome replication are a major driver of the genomic instability observed in cancer cells. To understand the molecular mechanisms by which eukaryotic cells carry out and monitor accurate genome replication we employ a fully reconstituted DNA replication system based on purified proteins from the budding yeast, S. cerevisiae. Research projects are focused on the mechanistic characterization of the DNA replication machinery, the mechanism of replication-coupled chromatin assembly, and the control of DNA replication by checkpoint genome surveillance pathways.
Yeast ORC sumoylation status fine-tunes origin licensing. Regan-Mochrie G, Hoggard T, Bhagwat N, Lynch G, Hunter N, Remus D, Fox CA, Zhao X. Genes Dev. 2022 Aug 4. doi: 10.1101/gad.349610.122. Online ahead of print.
A hypomorphic mutation in Pold1 disrupts the coordination of embryo size expansion and morphogenesis during gastrulation. Chen T, Alcorn H, Devbhandari S, Remus D, Lacy E, Huangfu D, Anderson KV. Biol Open. 2022 Aug 15;11(8):bio059307. doi: 10.1242/bio.059307. Epub 2022 Aug 8.
Dirk Remus, PhD
- Molecular biologist Dirk Remus investigates mechanisms of DNA replication in eukaryotic cells.
- PhD, University of California, Berkeley
- Louis V. Gerstner, Jr. Young Investigator Award, Memorial Sloan Kettering Cancer Center (2011)
- Long-Term Fellow, EMBO (2006)
To learn more about available postdoctoral opportunities, please visit our Career Center
To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Dirk Remus discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.